FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts.
FREQUENCY THERAPEUTICS
Industry:
Biotechnology Genetics Medical
Founded:
2015-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.frequencytx.com
Total Employee:
51+
Status:
Active
Contact:
866-389-1970
Email Addresses:
[email protected]
Total Funding:
76.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins Sitelinks Search Box
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Post-IPO Equity - Frequency Therapeutics
Wasatch Advisors
Wasatch Advisors investment in Post-IPO Equity - Frequency Therapeutics
Driehaus Capital Management
Driehaus Capital Management investment in Post-IPO Equity - Frequency Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Frequency Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Post-IPO Equity - Frequency Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Frequency Therapeutics
Federated Kaufmann Fund
Federated Kaufmann Fund investment in Post-IPO Equity - Frequency Therapeutics
Maven Investment Partners US
Maven Investment Partners US investment in Post-IPO Equity - Frequency Therapeutics
Mizuho Securities Principal Investment
Mizuho Securities Principal Investment investment in Series C - Frequency Therapeutics
Rivas Capital
Rivas Capital investment in Series C - Frequency Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-01-19 | Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer |
Official Site Inspections
http://www.frequencytx.com Semrush global rank: 2.54 M Semrush visits lastest month: 6.93 K
- Host name: 104.26.3.12
- IP address: 104.26.3.12
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Frequency Therapeutics"
Frequency Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 866-389-1970 Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.See details»
Frequency Therapeutics Headquarters & Corporate Office
Frequency Therapeutics is pioneering a new category in regenerative medicine. Frequency’s ...See details»
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Management and Organization Following the consummation of the merger, the combined company will be headquartered in Cambridge, Massachusetts. The combined company will ... For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx. …See details»
Frequency Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore Frequency Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 53 news, Disease Domain:Nervous System Diseases ...See details»
Frequency Therapeutics (USA) Funding: $138M - Medical Startups
Nov 7, 2024 USA | Funding: $138M Website: https://www.frequencytx.com Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.See details»
Working at Frequency Therapeutics - Zippia
Find out what it's like to work at Frequency Therapeutics. See what kind of people work at Frequency Therapeutics, career paths working at Frequency Therapeutics, company culture, salaries, employee political affiliation, and more.See details»
Frequency Therapeutics to Present 2021 Business and Pipeline …
Jan 5, 2021 WOBURN, Mass.--(BUSINESS WIRE)--Jan 5, 2021-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, …See details»
Frequency Therapeutics Expands Leadership Team with Newly …
Feb 7, 2020 For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx. Contacts Frequency Media Contact: Suzanne Day Frequency Therapeutics Tel: 781-496-2211 Email: sday ...See details»
Frequency Therapeutics, Inc. (Frequency Therapeutics, Inc.) - 药物 …
了解Frequency Therapeutics, Inc. (Frequency Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的8项临床试验, 86篇新闻，疾病领域:神经系统疾病，技术平台:小分子化药，寡核苷酸，药物:FX-345，Oligonucleotide Promoted Editing of RNA (Frequency …See details»
Frequency Therapeutics to Participate in September Investor and …
Aug 30, 2022 Investor: Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected] 617-914-0008 Media: Frequency Therapeutics Email: [email protected] Site Navigation HomeSee details»
Grant - Frequency Therapeutics - 2018-02-22 - Crunchbase
Feb 22, 2018 Organization Name . Frequency Therapeutics . Announced Date Feb 22, 2018; Funding Type Grant; Investors. Edit Investors Section. Number of ... Recent News. Edit Recent News Section. News • Apr 12, 2019. frequencytx.com — News & Events . Unlock even more …See details»
Frequency Therapeutics Announces New FX-322 Results Showing …
Sep 22, 2021 Media Contact: Suzanne Day Frequency Therapeutics Email: [email protected] Tel: 781-496-2211 Contacts Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations Email: [email protected] ...See details»
Frequency Therapeutics | Woburn MA - Facebook
Frequency Therapeutics, Woburn, Massachusetts. 1,020 likes · 1 was here. Frequency Therapeutics is working to advance regenerative medicine and develop a...See details»
Frequency Therapeutics Announces First Patient Dosed in
Dec 15, 2022 LEXINGTON, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has dosed a …See details»
Astellas and Frequency Therapeutics Enter into License Agreement …
Jul 22, 2019 The World Health Organization (WHO) estimates that there are currently more than 800 million adults with hearing loss globally. According to the U.S. National Institutes of Health, approximately 90 percent of those with hearing loss are affected by sensorineural hearing …See details»
Frequency Therapeutics Announces Topline Results for its
Feb 13, 2023 The Company’s lead preclinical program is designed to activate oligodendrocyte precursor cells with the goal of driving remyelination and potential functional recovery for individuals living with multiple sclerosis. For more information, visit www.frequencytx.com and …See details»
Frequency Therapeutics Releases New Data from Two FX-322 …
Mar 23, 2021 Media Contact: Suzanne Day Frequency Therapeutics Tel: 781-496-2211 Email: [email protected] Contacts Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations Tel: 617-914-0008 Email ...See details»
Frequency Therapeutics Completes Enrollment of Phase 2b Study …
Oct 12, 2022 Investor: Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected] 617-914-0008 Media: Frequency Therapeutics Email: [email protected] Site Navigation HomeSee details»
Frequency Therapeutics Releases New Data from Two FX-322 …
Mar 23, 2021 WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe …See details»
Frequency Therapeutics announces breakthrough small-molecule …
Feb 23, 2017 Another clinical trial for treating hearing loss is coming! Frequency Therapeutics released a press release Feb 21 describing “…a breakthrough small-molecule approach to regenerate inner ear sensory hair cells. Frequency is advancing the approach to develop a …See details»